An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV

被引:25
作者
Agadjanyan, MG
Trivedi, NN
Kudchodkar, S
Bennet, M
Levine, W
Lin, A
Boyer, J
Levy, D
Ugen, KE
Kim, JJ
Weiner, DB
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505B, Philadelphia, PA 19104 USA
[2] Russian Acad Med, Inst Viral Preparat, Moscow 129028, Russia
[3] Univ Alabama, Dept Med, Birmingham, AL 35243 USA
[4] Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA
[5] Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA
关键词
D O I
10.1089/aid.1997.13.1561
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously reported on the generation of specific functional immune responses after inoculation of animals with expression vectors encoding HIV-1 genes. This article provides the details of the first application of this new technology to induce immune responses against HIV-2. This virus is molecularly and serologically distinct from HIV-1 and is in fact more closely related to the simian immunodeficiency virus (SIV). Anti-HIV-2 and SIV antibodies were induced in mice of three different haplotypes following a single intramuscular inoculation with an HIV-2/ROD envelope glycoprotein expression vector (pcEnv-2). Boosting of animals with pcEnv-2 induced both anti-HIV-2 neutralizing antibodies and T cell-proliferative responses against HIV-2 and SIVmac proteins. We compared the humoral and cellular immune responses of mice injected with pcEnv-2 and then boosted with either the homologous DNA construct or a recombinant Env protein. Animals boosted with pcEnv-2 generated B and T cell immune responses as strong as those of mice boosted with recombinant gp140 protein in adjuvant. Finally, cellular immune responses were significantly increased with the coadministration of pcEnv-2 and a plasmid expressing interleukin 12, We therefore conclude that DNA plasmid inoculation induces cross-reactive anti-HIV-a and anti-SIVmac immune responses in mice, This technology should be further investigated as a potential vaccine component for this human pathogen.
引用
收藏
页码:1561 / 1572
页数:12
相关论文
共 67 条
  • [1] HUMORAL AND CELLULAR IMMUNE-RESPONSES IN RHESUS MACAQUES INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2
    ABIMIKU, AG
    FRANCHINI, G
    ALDRICH, K
    MYAGKIKH, M
    MARKHAM, P
    GARD, E
    GALLO, RC
    ROBERTGUROFF, M
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (03) : 383 - 393
  • [2] AGADJANYAN MG, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P47
  • [3] AGGARWAL A, 1991, INT C AIDS, V7, P16
  • [4] PROTECTION BY ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS IN MACAQUES AGAINST CHALLENGE WITH VIRUS-INFECTED CELLS
    ALMOND, N
    KENT, K
    CRANAGE, M
    RUD, E
    CLARKE, B
    STOTT, EJ
    [J]. LANCET, 1995, 345 (8961): : 1342 - 1344
  • [5] PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES
    BABA, TW
    JEONG, YS
    PENNINCK, D
    BRONSON, R
    GREENE, MF
    RUPRECHT, RM
    [J]. SCIENCE, 1995, 267 (5205) : 1820 - 1825
  • [6] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160
    BERMAN, PW
    GREGORY, TJ
    RIDDLE, L
    NAKAMURA, GR
    CHAMPE, MA
    PORTER, JP
    WURM, FM
    HERSHBERG, RD
    COBB, EK
    EICHBERG, JW
    [J]. NATURE, 1990, 345 (6276) : 622 - 625
  • [7] COMPARISON OF THE IMMUNE-RESPONSE TO RECOMBINANT GP120 IN HUMANS AND CHIMPANZEES
    BERMAN, PW
    EASTMAN, DJ
    WILKES, DM
    NAKAMURA, GR
    GREGORY, TJ
    SCHWARTZ, D
    GORSE, G
    BELSHE, R
    CLEMENTS, ML
    BYRN, RA
    [J]. AIDS, 1994, 8 (05) : 591 - 601
  • [8] BOYER J, 1996, J MED PRIMATOL, V25, P1
  • [9] Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
    Boyer, JD
    Ugen, KE
    Wang, B
    Agadjanyan, M
    Gilbert, L
    Bagarazzi, ML
    Chattergoon, M
    Frost, P
    Javadian, A
    Williams, WV
    Refaeli, Y
    Ciccarelli, RB
    McCallus, D
    Coney, L
    Weiner, DB
    [J]. NATURE MEDICINE, 1997, 3 (05) : 526 - 532
  • [10] BUSEYNE F, 1994, CLIN EXP IMMUNOL, V97, P353